Document is current

Article History

Received: 20 June 2024

Accepted: 12 December 2024

First Online: 11 February 2025

Acknowledgements

: Selected data were presented at the 84th meeting of the American Diabetes Association, 21–24 June 2024, Orlando, FL, USA.

: The datasets analysed during the current study are not publicly available due to participant confidentiality.

: Research reported in this publication was supported by Breakthrough T1D (formerly JDRF; Award number: 2-SRA-2022-1156-S-B). The content is solely the responsibility of the authors and does not necessarily represent the official views of Breakthrough T1D.

: BK, AD and FG report no personal financial disclosures but their institution has received study supplies from Medtronic and Dexcom. DMW reports funding from the NIH and Breakthrough T1D. RWB reports no personal financial disclosures but reports that his institution has received funding on his behalf as follows: grant funding and study supplies from Tandem Diabetes Care, Beta Bionics, and Dexcom; study supplies from Medtronic, Ascencia and Roche; consulting fees and study supplies from Eli Lilly and Novo Nordisk; and consulting fees from Insulet, Bigfoot Biomedical, vTv Therapeutics and Diasome. PC, CS, AKS, BIF, MAH, RV, JT, MA and SP declare that there are no relationships or activities that might bias, or be perceived to bias, their work.

: PC researched and interpreted the data and wrote the manuscript. CS performed statistical analysis and contributed to writing and reviewed the manuscript. AKS, BIF, MAH, BK, RV, JT, AD, FG, MA, DMW, SP and RWB researched data, contributed to the discussion and reviewed/edited the manuscript. All authors reviewed the work critically for important intellectual content and approved the final version submitted for publication. PC is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.